satavaptan

Known as: Benzamide, N-(1,1-dimethylethyl)-4-((cis-5'-ethoxy-4-(2-(4-morpholinyl)ethoxy)-2'-oxospiro(cyclohexane-1,3'-(3H)indol)-1'(2'H)-yl)sulfonyl)-3-methoxy- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
0246820062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Satavaptan, a vasopressin V2-receptor antagonist, has been shown to improve hyponatraemia in patients with cirrhosis… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
OBJECTIVE Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2012
2012
BACKGROUND AND OBJECTIVES Vaptans (vasopressin V(2)-receptor antagonists) are a new approach for the treatment of hyponatremia… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2012
2012
Gain-of-function mutations in the gene encoding the V2 vasopressin receptor (V2R) cause nephrogenic syndrome of inappropriate… (More)
Is this relevant?
2011
2011
AIMS Arginine vasopressin (AVP) V(2) receptor antagonism is a new approach to the management of hyponatraemia in congestive heart… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
BACKGROUND & AIMS Cirrhotic patients with recurrent ascites frequently require paracentesis despite diuretic therapy. Vasopressin… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2010
2010
BACKGROUND There is little information on the effects of vaptans in patients with cirrhosis. AIM To investigate the short-term… (More)
Is this relevant?
Review
2010
Review
2010
The increasing recognition of the risk of hyponatremia and its public health impact [1–4] has been matched by increasing interest… (More)
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
UNLABELLED Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2006
2006
The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V(2)-receptor antagonist, were investigated… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?